Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Chevron Corp (CVX) vs Invesco Ltd. (IVZ) Price & Performance

Chevron CorpTrade
Invesco Ltd.Trade

Price performance (Past 24H)

Key statistics

Chevron Corp vs Invesco Ltd. — how do they compare? Chevron Corp trades at $212.04 (market cap $414.98B), while Invesco Ltd. trades at $29.52 (market cap $13.28B). The key difference: Chevron Corp is far larger — about 31.2× Invesco Ltd.'s market cap, and Chevron Corp pays the higher dividend (3.37%). Which is the better fit depends on your goals — on Pluang, investors hold Chevron Corp for 101 Days and Invesco Ltd. for 77 Days on average.

CVXIVZ
Market Cap
$414.98B$13.28B
Volume
7,575,1123,698,033
Sector
EnergyFinancials
52-Week High
$217.73$33.31
52-Week Low
$146.72$22.44
Typical Hold Time
101 Days77 Days
Enterprise Value
$443.52B$23.45B
Dividend Yield
3.37%2.86%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Chevron Corp

CVX trades at $205.19, down 1.17% on the day, with a neutral technical signal and bullish moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $6.06 exceeding the $5.55 forecast. Revenue declined to $184.43B in 2025, but a rebound to $208.7B is projected for 2026. Analyst consensus is a Buy with a $208.31 price target, and the company maintains a strong balance sheet with $6.79B in cash.

CVX presents a mixed outlook; earnings beats and a favorable analyst consensus support upside, but declining revenue and net income margins pose risks. High oil prices and strategic investments, like the $13.8B Argentina project, offer growth potential, yet geopolitical tensions and volatile energy markets remain headwinds for shareholders.

Invesco Ltd.

Invesco (IVZ) trades at $29.51, down 3.25% today, with bearish technical signals dominating. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026, while Q3 2026 results are pending. Despite negative net income margins in 2025, operating cash flow remains strong at $1.53 billion, and analyst consensus leans toward Hold with a $33.71 price target. Recent news highlights ETF expansions and AUM growth to $2.56 trillion in August 2026.

The outlook is cautious; IVZ faces profitability challenges with negative ROE and net margins, but solid cash flow and analyst buy ratings (42.86%) suggest recovery potential. Risks include earnings volatility and competitive ETF pressures, while institutional sentiment is neutral. The stock's current price near the low end of analyst targets ($28-$41) may appeal to value investors betting on operational improvements.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CVX
23% Buy77% Sell
Avg holding period · 101 Days
IVZ

No sentiment data available yet.

Top news

Latest headlines on both assets

About Chevron Corp

Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.

Read more on CVX →

About Invesco Ltd.

Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).

Read more on IVZ →